Dermata Therapeutics, Inc.
DRMA
$1.29
$0.1210.26%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 41.49% | 12.40% | 2.08% | -9.51% | -16.14% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -36.82% | -37.88% | -21.32% | 4.14% | 29.90% |
| Operating Income | 36.82% | 37.88% | 21.32% | -4.14% | -29.90% |
| Income Before Tax | 38.00% | 38.49% | 21.50% | -5.22% | -31.86% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 38.00% | 38.49% | 21.50% | -5.22% | -31.86% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 38.00% | 38.49% | 21.50% | -5.22% | -31.86% |
| EBIT | 36.82% | 37.88% | 21.32% | -4.14% | -29.90% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 91.51% | 92.65% | 91.00% | 85.88% | 75.73% |
| Normalized Basic EPS | 91.51% | 92.65% | 91.00% | 85.88% | 75.73% |
| EPS Diluted | 91.51% | 92.65% | 91.00% | 85.88% | 75.73% |
| Normalized Diluted EPS | 91.51% | 92.65% | 91.00% | 85.88% | 75.73% |
| Average Basic Shares Outstanding | 514.74% | 441.55% | 742.29% | 899.09% | 835.52% |
| Average Diluted Shares Outstanding | 514.74% | 441.55% | 742.29% | 899.09% | 835.52% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |